Search results
Results From The WOW.Com Content Network
On Friday, Nasdaq Inc’s (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on December 23. Illumina, Inc. (NASDAQ:ILMN) was removed from ...
(Reuters) -A U.S. appeals court on Friday struck down a Federal Trade Commission order against Illumina's purchase of cancer diagnostic test maker Grail, a former subsidiary, saying the agency had ...
Even still, Icahn is pressing on with a lawsuit he filed against the Illumina board of directors last year. In the suit, Icahn accused the board of breaching their fiduciary duty by completing the ...
The European Union on Wednesday slapped a $475 million fine on U.S. biotech giant Illumina for buying cancer-screening company Grail without regulators' approval, the latest setback for the deal.
Illumina's stock price has tumbled more than 37% so far this year, and the board replaced the CEO soon after Icahn won one board seat. Icahn did not immediately respond to Reuters request for comment.
Illumina claimed that Oxford Nanopore infringed its patents on the use of a biological nanopore, Mycobacterium smegmatis porinA (MspA), for sequencing systems. [64] [65] In August 2016 the parties settled their lawsuit. [66] In February 2020, Illumina filed a patent infringement suit against BGI relating to its "CoolMPS" sequencing products. [67]
The European Union on Thursday ordered U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators in ...
Illumina Inc., 437 F. Supp. 2d 252 (D. Del. 2006), was a United States patent law case heard before the United States District Court for the District of Delaware. In its ruling, the district court was the first court to hold that reputational harm could be sufficient to establish standing in an action for correction of named inventor under 35 U ...